Replimune Group Inc.'s presentation at the JPM Healthcare Conference on January 14, 2026, highlighted their innovative approach to oncolytic immunotherapy.
The company is focused on activating a systemic immune response to combat cancer by leveraging their RPx Platform.
Key elements of their strategy include deep injections, image-guided treatments, and expanding beyond skin cancer into other challenging areas.
Replimune's platform aims to drive robust local and distant anti-tumor responses for improved patient outcomes.
RPx Platform Advances
Focused on activating systemic immune responses through deep and superficial injections.
Clinical Trial Progress
Near-term PDUFA date of April 10, 2026, for melanoma treatment, with promising results seen in patients.
Expansion Plans
Moving beyond skin cancer to address liver, lung, and other difficult-to-treat cancers with RPx therapy.
Patient Impact
Over 1,000 patients treated across the RPx Platform, showing durable activity and systemic effects.
- Replimune's approach marks a significant advancement in oncolytic immunotherapy, targeting deep lesions and difficult-to-treat settings.
- Their focus on activating systemic immune responses opens new possibilities for cancer treatment, potentially improving outcomes for patients with challenging cancers.
Replimune Group Inc.'s RPx Platform holds promise in revolutionizing cancer treatment through oncolytic immunotherapy. With a strong emphasis on deep injections and systemic immune activation, their approach could pave the way for improved patient outcomes in challenging cancer cases.